コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 he high rate of acute rejection, sepsis, and posttransplantation lymphoproliferative disorder.
2 ronic rejection and the other as a result of posttransplantation lymphoproliferative disorder.
3 ing off immunosuppression for treatment of a posttransplantation lymphoproliferative disorder.
4 d neoplastic bowel obstruction, three due to posttransplantation lymphoproliferative disorder and one
6 Here we report an unusual presentation of posttransplantation lymphoproliferative disorder as unil
7 e patient who was treated with CsA developed posttransplantation lymphoproliferative disorder during
8 e two episodes of Epstein Barr virus-related posttransplantation lymphoproliferative disorder, one of
10 nce of (18)F-FDG PET/CT for the detection of posttransplantation lymphoproliferative disorder (PTLD)
11 oma, and also distinguished untreated, EBV(+)posttransplantation lymphoproliferative disorder (PTLD)
13 e increased risk of Epstein-Barr virus (EBV) posttransplantation lymphoproliferative disorder (PTLD)
14 following rituximab-based chemotherapy for a posttransplantation lymphoproliferative disorder (PTLD)
16 t died from Epstein-Barr virus (EBV)-related posttransplantation lymphoproliferative disorder (PTLD)
20 terature describing the relationship between posttransplantation lymphoproliferative disorder (PTLD)
23 oproliferation consistent with a polymorphic posttransplantation lymphoproliferative disorder (PTLD).
25 ffective for the treatment of EBV-associated posttransplantation lymphoproliferative disorders (PTLDs
26 271 centers worldwide to define patterns of posttransplantation lymphoproliferative disorders (PTLDs
27 Posttransplantation lymphoproliferative disorders (PTLDs
28 EBV(-) posttransplantation lymphoproliferative disorders (PTLDs
29 ll transplant recipients are associated with posttransplantation lymphoproliferative disorders (PTLDs
30 1 year for belatacept, but the incidence of posttransplantation lymphoproliferative disorder was hig